Is There a Role for Dose Modification of TKI Therapy in CML?
Author:
Open Access
- 14 June 2019
- journal article
- review article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 14 (4) , 337-345
Abstract
Purpose of Review For patients with chronic phase chronic myeloid leukemia (CP-CML), there is an increasing focus on personalization of therapy with dose modifications of tyrosine kinase inhibitors (TKIs) to reduce side effects and maintain efficacy. Dose reductions are also being considered in clinical trials prior to treatment-free remission (TFR) attempts. Recent Findings Recent retrospective analyses of large clinical trials show that dose modification/reduction is safe. Efficacy is generally maintained and side effects are improved. Clinical trials such as DESTINY have demonstrated that dose reduction is safe for patients in deep molecular remission and may be considered prior to a TFR attempt. Summary Dose modifications are widely used to prevent and manage the toxicities of TKIs. With adequate monitoring, dose optimization is safe, reduces side effects, and improves quality-of-life for patients. Clinical trials of dose optimization are currently recruiting across all approved TKIs and will lead to further personalization of therapy for CP-CML patients in the future.Keywords
Funding Information
- University of Glasgow
This publication has 49 references indexed in Scilit:
- Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinibAnnals of Hematology, 2013
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)Blood, 2012
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemiaCancer, 2010
- Clinical impact of dose reductions and interruptions of second‐generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaBritish Journal of Haematology, 2010
- Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapyBlood, 2008
- Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia, 2008
- Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006